Sevion Therapeutics Presents Antibody Discovery Platform at International Conference
SAN DIEGO, CA – September 22, 2015 – Sevion Therapeutics, Inc. (“Sevion” or the “Company”)(OTCBB: SVON), a biopharmaceutical company which discovers, develops, and acquires next-generation biologics for the treatment of cancer and immunological diseases, today announced that Dr. Vaughn Smider, M.D., Ph.D., Chief Scientific Officer, will give a presentation entitled “Antibody Discovery against Multipass Membrane Proteins Directly on the Cell Surface” at the Discovery On Target Drug Discovery conference in Boston, MA on September 24, 2015, as an invited speaker. Dr. Smider noted, “our unique discovery platform, used in our internal discovery efforts as well as large pharma partners, provides a proprietary position in the discovery of monoclonal antibodies against particularly challenging multipass membrane protein targets. With the antibody therapeutics market well validated with now over $50B per year in sales, we believe we are at the forefront in pioneering the next-generation of antibody discovery technologies.” Dr. Smider added, “the first generation of our technology was featured in Nature Biotechnology several years ago, and we are now eager to share the advancements we’ve made in our spatially addressed antibody discovery system in generating leads directly on the cell surface – an important strategy for finding drug leads against challenging targets.”
About Sevion Therapeutics
Sevion Therapeutics is a biopharmaceutical company building and developing a portfolio of innovative therapeutics, from both internal discovery and acquisition, for the treatment of cancer and immunological diseases. The Company’s product candidates are derived from multiple key proprietary technology platforms: cell-based arrayed antibody discovery, ultralong antibody scaffolds and Chimerasome nanocages. Sevion has leveraged these technologies to build a pipeline of innovative product candidates. For more information, please visit SevionTherapeutics.com.
Certain statements included in this press release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from such statements expressed or implied herein as a result of a variety of factors, including, but not limited to: the Company’s ability to continue as a going concern; the ability of the Company to consummate additional financings; the development of the Company’s gene and antibody technology; the approval of the Company’s patent applications; the Company’s ability to successfully defend its intellectual property or obtain the necessary licenses at a cost acceptable to the Company, if at all; the successful implementation of the Company’s research and development programs and collaborations; the success of the Company’s license agreements; the acceptance by the market of the Company’s products; the timing and success of the Company’s preliminary studies, preclinical research and clinical trials; competition and the timing of projects and trends in future operating performance; and the quotation of the Company’s common stock on an over-the-counter securities market, as well as other factors expressed from time to time in the Company’s periodic filings with the Securities and Exchange Commission (the “SEC”). As a result, this press release should be read in conjunction with the Company’s periodic filings with the SEC. The forward-looking statements contained herein are made only as of the date of this press release, and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.
For investors contact: